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flox/flox ('Acinar:KP cKO ')) in mice. We then performed a thorough analysis of the resulting histopathological changes. results Both mouse models developed PDac, but Duct:KP cKO mice developed PDac earlier than Acinar:KP cKO mice. tumour development was more rapid and associated with high-grade murine Panin (mPanin) lesions in Duct:KP cKO mice. in contrast, Acinar:KP cKO mice exhibited widespread metaplasia and low-grade as well as high-grade mPanins with delayed progression to PDac. acinar-cellderived tumours also had a higher prevalence of mucinous glandular features reminiscent of early mPanin lesions. Conclusion these findings indicate that ductal cells are primed to form carcinoma in situ that become invasive PDac in the presence of oncogenic Kras and Trp53 deletion, while acinar cells with the same mutations appear to require a prolonged period of transition or reprogramming to initiate PDac. Our findings illustrate that PDac can develop in multiple ways and the cellular context in which mutations are acquired has significant impact on precursor lesion initiation, disease progression and tumour phenotype.
InTrODuCTIOn
Pancreatic ductal adenocarcinoma (PDAC) is characterised as a mass of haphazard ductules arranged in a desmoplastic stroma. The histological similarity of these ductules and associated precancerous lesions, called pancreatic intraepithelial neoplasia (PanIN), to pancreatic ductal cells suggested a lineage relationship and led to the development of tumour progression models that featured the normal ductal cell as the cellular origin of PDAC. 1 In these models, oncogenic Kras, one of the most common mutations in PDAC, is proposed to initiate low-grade PanIN from ductal cells. These lesions then acquire additional mutations, such as p16 or p53 loss, before becoming high-grade PanIN 
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invasive PDAC. 1 However, acinar cells were found in early metaplastic ductules 2 3 and lineage traced into a ductal-cell-like fate, 4 5 suggesting that acinar cells could act as a cellular origin for PDAC. Indeed, multiple studies have shown that oncogenic Kras expression in murine acinar cells triggers widespread ductal metaplasia, murine PanIN (mPanIN) as well as PDAC. [6] [7] [8] [9] [10] [11] In contrast, oncogenic Kras expression in ductal cells induces only a small number of low-grade mPanIN. 10 12 In sum, experimental evidence predominantly supports the potential of acinar cells to initiate mPanIN and PDAC; however, the data regarding ductal cell potential are limited.
Although ductal cells can contribute to mPanINs, 10 12 whether these ductal-cell-derived lesions progress in the same manner as acinar-cell-derived mPanIN or whether they are viable cell of origin for PDAC is unclear. Recent studies have started to directly compare the potential of acinar and ductal cells to initiate PDAC. 6 13 14 Using mouse models, these studies show that both ductal and acinar cells have the potential to form PDAC. 6 13 14 However, the acinar-cell-derived or ductal-cell-derived tumours were formed under different treatment conditions or with different genetic mutations 6 13 14 ; therefore, it remains unclear whether the differences in tumour development or phenotype observed were a result of the treatment conditions, mutation combination or cellular origin. Thus, studies to specifically examine the cell-of-origin-specific effects are needed and could highlight the initiating cell as a source of PDAC heterogeneity.
To isolate the effect of cell of origin alone on PDAC initiation, development and phenotype, we used CreER-inducible mouse models to make the same genetic changes, expression of oncogenic Kras G12D and ablation Trp53 (occurring in ~92% and ~27% of human PDAC samples, respectively 15 ), in ductal or acinar cells. We found that cell of origin alone can impact the initiation and phenotype of PDAC.
MATerIAls AnD MeTHODs Mice
All described animal experiments were approved by the University of British Columbia and University of California, San Diego Animal Care and Use Committees. The sources and phenotypes for the mouse strains, as well as details of genotyping and endpoint monitoring strategies, are provided as online Supplemental Information. Recombination was induced by three subcutaneous injections of tamoxifen in corn oil (20 mg/mL) over 5 days at 0.125 g tamoxifen/g body mass.
Histology, immunohistochemical and immunofluorescence analyses
Paraffin-embedded or frozen sections were prepared and stained using haematoxylin and eosin, Alcian blue, immunohistochemical or immunofluorescence stains as described previously. 10 16-18 Histological and morphometric analyses were conducted by AYLL and JLK independently and verified by DFS (gastrointestinal pathologist). Detailed descriptions of staining and morphological assessment methods, as well as the antibodies used, are provided as online Supplemental Information.
statistical analysis
Normal distribution, F-test of variance, and parametric and non-parametric P values were calculated in GraphPad Prism or Excel or statistical programming language R, V.3.4.1 (R Core Development Team, 2017) software. GraphPad Prism was used to calculate the mean and SEM. We performed a linear regression using the statistical programming language R, V.3.4.1 (R Core Development Team, 2017) to test if there was a significant (P<0.05) relationship between time post-tamoxifen injection and tumour number or size.
resulTs loss of Trp53 and activation of Kras in ductal compared with acinar cells shortens survival in mice
To determine how cellular origin affects the initiation and progression of PDAC, we generated mouse models in which a shared set of PDAC-associated mutations 15 19 20 in Kras and Trp53 were induced in a cell-type-specific manner. Specifically, we used the Cre-dependent Kras LSL-G12D 21 and Trp53 flox conditional alleles 22 to activate Kras and ablate p53 expression, respectively. To trace the fate of recombined cells, we also included a Cre-dependent R26R YFP reporter allele. 23 Finally, Cre-mediated recombination was induced in adult ductal or acinar cells using the tamoxifen-inducible Sox9CreER transgene 18 24 or Ptf1a CreER allele, 25 respectively. By combining all of these alleles through cross-breeding and injecting the offspring with tamoxifen at 3 to 4 weeks of age ( figure 1A, B figure  S1A , B). As previously reported, 24 25 little or no recombination of the R26R YFP allele was observed in uninjected mice with the Sox9CreER or Ptf1a
CreER allele, respectively (online supplementary figure S1C).
To examine the effect of activating Kras and ablating Trp53 on ductal and acinar cells, we injected a cohort of Duct:KP cKO (n=19) and Acinar:KP cKO (n=9) mice with tamoxifen at 3 to 4 weeks of age and monitored the animals until their humane endpoint (figure 1B). In addition to the pancreas, this Sox9CreER allele 24 is expressed in the oral mucosa, mammary gland and lung. Therefore, 11 Duct:KP cKO mice reached their humane endpoint due to non-pancreatic masses, were censored from the PDAC-specific survival curve and excluded from further analysis ( figure 1C ). The remaining Duct:KP cKO mice (n=8) reached their humane endpoint within 10-13 weeks post-tamoxifen injection ( figure 1C ). In contrast, Acinar:KP cKO mice reached their humane endpoint at 15-23 weeks post-tamoxifen injection ( figure 1C ). On necropsy, we found pancreatic tumours (figure 1D) 
Cell of origin affects PDAC histology and timing
To determine whether differences in the survival outcomes of Duct:KP cKO and Acinar:KP cKO mice were due to distinct tumour attributes, we extensively characterised the tumours in Duct:K-P cKO and Acinar:KP cKO mice. Pancreata from both Duct:KP cKO and Acinar:KP cKO mice, but not controls, had solid tumour nodules, ranging from small, distinct nodes to complete displacement of the normal parenchyma by tumours ( figure 1D Pancreas S3). However, areas of well-differentiated and poorly differentiated epithelium were also present (online supplementary figure  S3A ) that had higher and lower amounts of stroma, respectively (online supplementary figure S3B, C). Interestingly, a number of tumours from Acinar:KP cKO mice, but rarely Duct:KP cKO mice, were composed of atypical glands with abundant supranuclear mucin resembling mPanIN lesions (denoted as 'Mucinous-gland') or larger atypical gland structures (denoted as 'Large-gland') ( figure 2D and table 1 figure 3 ). In addition, no difference in the size, number or location of individual tumours was observed (online supplementary figure S4A-C) figure 4B, P=0.2632) . Once tumours formed in Acinar:KP cKO mice, though, their size significantly increased with time (figure 4C, P<0.001) suggesting that growth was a more dominant mechanism than tumour initiation in the acinar-cell-derived mouse model. Taken together, these data suggest that differences in the time of PDAC initiation resulted in the distinct survival intervals of Duct:KP cKO and Acinar:KP cKO mice. In support of this, the 4-week delay in tumour initiation observed in the Acinar:KP cKO mouse model approximately matched the difference in time (34 days) between the first animals of each model succumbing to the disease ( figure 1C and table 1 figure 5A, B) . We also found high-grade mPanIN in Acinar:KP cKO mice beginning at 4 weeks post-injection and the number increased to approximately 20 mPanIN3 lesions per section per mouse by 16 weeks post-injection ( figure 5B ). This suggests that a progression from low-grade to high-grade mPanIN could occur from Kras G12D -expressing acinar cells in the absence of Trp53. In contrast, we found a small number of mPanIN3, but no mPanIN1, lesions in Duct:KP cKO mice at all time points analysed ( figure 5A, B) . Interestingly, the number of mPanIN3 lesions in Duct:KP cKO and Acinar:KP cKO mice were comparable at 4 weeks post-injection (~1 per section per mouse) (figure 5B). However, Duct:KP cKO mice already had small microtumours at this time point (figure 4B, C), while Acinar:KP cKO mice did not develop invasive lesions for another month ( figure 4B ). Together, these data suggest that the reduced survival time of Duct:KP cKO compared with Acinar:KP cKO mice may be due to the increased propensity of Kras G12D -expressing ductal cells to induce mPanIN3 that convert to invasive PDAC in the absence of Trp53.
To ensure that the discrepancy in mPanIN3 progression was not due to differential recombination of the Trp53 flox allele in Kras G12D -expressing acinar and ductal cells, we used p53 immunohistochemistry to examine p53 status in mPanIN from Duct:KP cKO and Acinar:KP cKO pancreata. Ductal-cell-derived and acinar-cell-derived mPanIN3 were both uniformly p53-negative (online supplementary figure S6A ), suggesting that these lesions arose from Trp53-ablated cells. Thus, the presence of p53 does not explain the delayed progression of acinar-cell-derived mPanIN3 to PDAC. In contrast to mPanIN3 lesions, p53 expression in the acinar-cell-derived low-grade mPanIN was more variable with some lesions completely lacking p53, and others expressing high levels of p53 (online supplementary figure S6B) . Thus, the large parenchymal area displaced by abnormal duct-like lesions (approximately 30%) (online supplementary figure S6C ) in some Acinar:KP cKO pancreata is likely composed of low-grade Kras G12D+ p53 − and Kras G12D+ p53 + lesions, while mPanIN3 and PDAC arise from Kras G12D+ p53 − cells. To examine potential differences between acinar-cell-derived and ductal-cell-derived mPanIN3, we examined whether cell death or proliferation might differ in these lesions. We found little to no cell death, as denoted by cleaved caspase 3 positivity, in the mPanIN3 lesions (online supplementary figure S6D) , and the average per cent of Ki67 + cells per mPanIN3 was similar between cellular origins ( figure 5C, D, P=0.09792) . However, the variance in the number of proliferating cells between the ductal and acinar cell model was significantly different ( figure 5D, F-test, P=0.01372 ). This suggests that there was more heterogeneity in the proliferative rate of acinar-cell-derived compared with ductal-cell-derived mPanIN3 lesions, which could underlie some of the differences in mPanIN3 progression between cellular origins.
Acinar-cell-derived PDAC often retains molecular properties associated with low-grade mPanIn
Because mucinous low-grade mPanINs were more prevalent in Acinar:KP cKO compared with Duct:KP cKO mice (figure 5B) and tumours derived from acinar cells tended to contain more highly mucinous glands ( figure 2D and table 1 ), we next asked whether tumours formed from acinar cells might retain a molecular 'memory' of their transition through a low-grade mucinous mPanIN stage. To address this question, we examined whether acinar-cell-derived PDAC maintained characteristics typical of low-grade mPanINs, such as expression of acidic mucins or Mucin 5AC (Muc5AC). 26 We found that acinar-cellderived tumours had moderate to strong levels of Alcian blue (acidic mucin stain) and Muc5AC staining that frequently, but not exclusively, correlated with histological areas containing mucinous glands ( figure 6A-C) . Quantification of the per cent total tumour area occupied by Alcian blue + or Muc5AC + glands in Acinar:KP cKO and Duct:KP cKO mice (n=8 for each genotype) illustrated that acinar-cell-derived tumours on average contained more acidic mucins and Muc5AC expression than ductal-cell-derived PDAC (figure 6C, D, P<0.001 and P<0.05, respectively). Importantly, the Alcian blue and Muc5AC positivity was not restricted to tumours we previously characterised as 'large-gland' or 'mucinous-gland', but was found in a larger number of acinar-cell-derived PDAC. Altogether, our data showed that low-grade mPanIN characteristics and premalignant low-grade mPanINs are highly associated with acinar-cell-derived but not ductal-cell-derived PDAC. This suggests that the developmental route of acinar-cell-derived and ductal-cell-derived tumours in mice can impact tumour histopathology, as well as the molecular phenotype.
Recent studies have described a number of different PDAC subtypes. To determine whether acinar-cell-derived or ductalcell-derived PDAC may be similar to these molecular subtypes, we performed immunohistochemistry for one of the markers associated with the 'classical' PDAC subtype, Keratin 20 (CK20). 27 We found that the signal for this marker was very intense in the highly mucinous glands of acinar-cell-derived PDAC (figure 6E). Quantification of CK20 signal in ductal-cell-derived and acinarcell-derived PDAC indicates that CK20 is significantly higher in acinar-cell-derived compared with ductal-cell-derived tumours ( figure 6F ). This suggests that at least some of the acinar-cell-derived tumours may be similar to the 'classical' subtype of PDAC. However, a more comprehensive analysis of multiple markers is needed before cell of origin can be implicated as a source of heterogeneity in PDAC.
Pancreas DIsCussIOn
Ductal cells are a cellular origin of mPanIn-associated PDAC
Our study demonstrates that Kras G12D -expressing ductal cells quickly form high-grade mPanIN and convert to PDAC in the absence of Trp53. The absence of low-grade PanIN, which readily form from acinar cells, 8 10 11 16 in Duct:KP cKO mice even though a small number of Cpa1 + cells are labelled by the Sox9CreER allele argues that acinar cells are not contributing to the tumourigenesis observed in Duct:KP cKO mice. In addition, the absence of low-grade mPanIN in our study, as well as that of Bailey et al, 6 suggests that ductal cells do not need to transition through a low-grade mPanIN stage to form PDAC in the absence of functional Trp53. Typically, only PanIN3 and PDAC are thought to possess mutations in Trp53. 28 29 Thus, the animal models in ours and Bailey et al 6 studies may provide G12D -expressing ductal cells form low-grade mPanINs. 10 12 Although the tumourigenic potential of the ductal-cell-derived mPanINs were not examined in previous studies, 10 12 our subsequent studies demonstrated that loss of the tumour suppressor Pten alone (Sox9CreER;Pten flox/ flox mice) in ductal cells could result in low-grade as well as highgrade mPanIN that were associated with PDAC in the context of large duct metaplasia. 30 In addition, combining oncogenic Kras expression with heterozygous loss of Pten in ductal cells (Sox9CreER;Kras
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mutations sufficient for tumour formation and result in ductal cells bypassing the low-grade mPanIN stage. Importantly, these findings do not supersede previous observations that Kras
LSL-G12D
;Pten flox/+ mice) promoted mPanIN-associated PDAC induction. 30 Although our studies suggest that ductal cells are capable of initiating tumourigenesis via the proposed PanIN progression model, 1 this is likely dependent on genetic context and PanINs may not always be necessary. Thus, the current PanIN progression model 1 may only capture a simplified picture of the way tumours develop, and this model may need to be revised to incorporate the context of specific genetic mutations and distinct cells of origin.
Acinar-cell-derived tumourigenesis is delayed and more stochastic than ductal-cell-derived tumourigenesis
In contrast to Duct:KP cKO mice, Acinar:KP cKO mice develop the entire spectrum of low-grade to high-grade mPanIN lesions from Kras G12D -expressing p53-negative cells. This suggests that acinar-cell-derived mPanINs might follow a progression model where low-grade mPanIN precede high-grade mPanIN.
1 Unlike ductal cells, acinar cells must change a large portion of their transcriptional programme to become ductal-cell-like mPanIN and PDAC. Thus, it is possible that this acinar-to-ductal-cell-like transition slows the initiation of PDAC from most Kras G12D -expressing, p53-deleted acinar cells and favours the accumulation of lesions at multiple stages of the acinar-cell-to-PDAC progression scheme. 16 In support of this theory, we found (1) mPanIN lesions of all grades accumulate with time in Acinar:K-P cKO mice; (2) some acinar-cell-derived PDAC had large areas of highly mucinous glands and maintained strong expression of low-grade mPanIN markers; and (3) the duration of time until Acinar:KP cKO mice initiated tumours or reached their humane endpoint varied widely from mouse to mouse, but was very predictable for the Duct:KP cKO mouse model. Altogether, these data suggest that acinar-cell-mediated tumourigenesis may be a halting or stochastic process requiring additional epigenetic or genetic events to occur for progression to PDAC. As a result of this randomised process of progression, we might expect that PDAC arising from acinar cells would be more heterogeneous. Consistent with this, we observed a greater number of histological phenotypes and variability in mucin and CK20 expression in acinar-cell-derived versus ductal-cell-derived PDAC. Thus, the process of acinar-cell-to-PDAC transformation, at least in mice, is highly variable and results in more intertumoural heterogeneity.
Not only are acinar-cell-derived and ductal-cell-derived PDAC associated with different grade of mPanIN, it appears that mPanIN3 derived from acinar cells are not equivalent to those from ductal cells. A number of possible brakes or checkpoints could underlie the differences in acinar-cell-derived versus ductal-cell-derived tumourigenesis from mPanIN3. For example, previous studies have shown that the acinar-cell-differentiation programme limits the number of acinar cells switching to the ductal-cell-like mPanIN fate in response to the Kras oncogene. [31] [32] [33] [34] [35] Moreover, removing Kras G12D reverts these mPanIN cells to the acinar cell fate. 36 Thus, the transcriptional or epigenetic status of the terminally differentiated acinar cell may persist for some time once they have converted to duct-like cells and potentially limit PDAC initiation. Although a similar transcriptional mechanism for the ductal cell fate has been proposed to limit induction of cystic precursor lesions from ductal cells, 37 the role of this programme in ductal-cell-mediated mPanIN and PDAC is unknown. Another potential cellular programme known to limit acinar-cell-mediated mPanIN and PDAC formation is oncogene-induced senescence. Guerra and colleagues demonstrated that Kras G12V expression in acinar cells induces low-grade mPanIN lesions that become senescent or growth arrested. 38 Thus, induction of cell cycle arrest proteins, like p16, might be important for halting acinar-cell-derived tumourigenesis. In support of this, we observed a greater variation in proliferation in acinar-cell-derived PanIN3 lesions compared with their ductalcell-derived counterparts. This variation could be due to localised inflammation that previous studies demonstrated reduced the growth-arrested phenotype in acinar-cell-derived mPanIN. 38 This suggests that increased inflammation due to pancreatitis could specifically decrease the latency of acinar-cell-derived tumourigenesis. The role of senescence in ductal-cell-mediated mPanIN formation and progression, however, is unclear and the growth arrest associated with Kras G12D expression may not occur in this cell type or it may be completely dependent on p53.
Finally, the biggest difference between Acinar:KP cKO and Duct:KP cKO mice is the quicker transition of ductal-cell-derived mPanIN3, or ductal carcinoma in situ, into invasive lesions. Therefore, the increased propensity of cells within ductal-cellderived mPanIN to invade the basement membrane and move into the stroma becoming PDAC could underlie the differences in mPanIN3 derived from different cell types. Consistent with a role for invasion in the difference between ductal-cell-derived and acinar-cell-derived tumourigenesis, we observed metastases to the diaphragm and peritoneum in two Duct:KP cKO mice, but distant metastases were not present in Acinar:KP cKO mice. While these observations are based on a limited number of animals, the data support the conclusion that ductal-cell-derived tumourigenesis is associated with a more invasive phenotype. Additional studies examining the differential expression of factors involved in cell-to-cell adhesion or the epithelial-to-mesenchymal transition could illuminate potential molecular mechanisms underlying this difference in invasiveness. In sum, future studies are needed to examine each of these specific candidate programmes to gain mechanistic insight into why ductal-cell-derived mPanIN induce PDAC more rapidly than their acinar-cell-derived counterparts.
Impact of more than one cellular origin of PDAC on preclinical PDAC models
Many studies have characterised the specific effects of distinct genetic mutations on PDAC initiation and development, with the majority of studies using pan-pancreatic mouse models driven by combining the Pdx1-Cre or Ptf1a
Cre alleles with the Kras LSL-G12D allele and conditional knockout alleles for the gene of interest. [39] [40] [41] [42] This would result in both acinar and ductal cells expressing oncogenic Kras and losing expression of the gene of interest. In the case of Trp53, evidence from our study and that of Bailey et al 6 would suggest that ductal and acinar cells respond differently to whether the activity of one or both alleles of Trp53 is lost. 6 Specifically, Bailey et al 6 found that heterozygous Trp53R172H mutations in Kras G12D -expressing acinar but not ductal cells induced PDAC. In contrast, we found homozygous disruption of Trp53 in both Kras G12D -expressing ductal and acinar cells induced PDAC, but acinar cells required more time for PDAC induction. 6 This suggests there may be cell-of-origin-specific effects at play in pan-pancreatic mouse models that have been previously unrecognised. For example, our data would predict that the first tumours observed in ;Trp53 R172H/R172H mice could instead be ductal-cell derived due to faster carcinoma initiation from this cell type. It is possible that other confounding factors, such as any effect of the embryonic context, may complicate whether observations in our cell-type-specific mouse models could be simply extrapolated to embryonically induced pancreatic cancer models. Nevertheless, it is clear from our studies and others 6 9 14 that even subtly changing the genetic context (homozygous vs heterozygous mutation) could dramatically change the PDAC cellular origin and potentially tumour phenotype. Therefore, greater care should be taken to analyse genetic mutations in the context of the adult cell types from which PDAC likely arises.
significance of more than one PDAC cell of origin
We have shown that cell of origin is an important factor to consider when using mouse models to study PDAC. It can affect tumour initiation and progression and may also affect the tumour phenotype. This raises the possibility that cell of origin may underlie the generation of interpatient tumour heterogeneity and differential clinical outcomes. Interestingly, one of the main phenotypes distinguishing acinar-cell-mediated and ductal-cell-mediated tumourigenesis appears to be the accumulation of low-grade and high-grade mPanIN lesions during acinar-cell-mediated tumourigenesis. Recent studies examining the number of PanIN lesions of different grades adjacent to resected tumours have found that patients can be separated into two general groups: those with the entire spectrum of PanIN lesions (PanIN1-3) and those with no PanIN3 and little or no PanIN1. [43] [44] [45] Interestingly, the latter patients have a significantly worse prognosis compared with those who had a higher number of PanINs. Because PanINs that give rise to PDAC are likely obscured by the growing tumour, a larger number of PanINs present in the resection margin is likely the result of a field effect. In addition, Kras G12D -expressing acinar cells are more susceptible to inflammation and more easily give rise to mPanIN. Therefore, the accumulation of PanINs in the resected margin may indicate that these patients have a predisposition for their acinar cells to induce tumours. However, those patients with very little evidence of a field effect may have been predisposed to form ductal-cell-derived PDAC that developed with very little impact on the rest of the pancreatic parenchyma. While our data suggest just one possibility to explain the aforementioned correlates, definitively connecting these clinical observations with our observations of tumourigenesis in mouse models will require generation of transcriptional or genetic signatures of acinar-cell-specific and ductal-cell-specific tumours. These signatures could then be correlated with clinical outcomes to examine the role of cellular origin in human PDAC.
